Jefferies Rates Molbio Buy, Stock Surges 9% on Innovation Focus

Jefferies Initiates ‘Buy’ Rating on Molbio, Stock Climbs 9% Amid Innovation Focus

Molbio Diagnostics sees a significant uptick in stock price as Jefferies highlights its innovative growth potential.

Strong Market Reaction

Molbio Diagnostics experienced a robust 9% increase in its stock price during Wednesday’s trading session, following Jefferies’ initiation of coverage with a ‘Buy’ rating. The stock reached a high of ₹1,369.20 on the National Stock Exchange (NSE) before settling at ₹1,317.80, reflecting a strong market response to the investment bank’s positive outlook. This surge is particularly notable given that the stock has been trading approximately 70% above its initial public offering (IPO) price of ₹807 since its debut on August 17, 2026.

Jefferies’ Bullish Outlook

Jefferies has positioned Molbio as a ‘high-conviction pick’, assigning a target price of ₹1,600, which suggests a substantial upside potential of 27% from its last closing price. The investment bank’s analysis highlights Molbio’s innovative approach to molecular diagnostics, particularly its Truenat platform, which is designed for point-of-care testing. Jefferies expects the company to capitalize on its existing product lines while also expanding into new markets, including the commercial rollout of its Optrascan platform in the United States.

Growth Drivers and Financial Projections

Analysts at Jefferies anticipate that Molbio will achieve a compound annual growth rate (CAGR) of 22% in revenue and a staggering 47% in profit after tax (PAT) from FY26 to FY29. This growth is expected to be driven by the expansion of the Truenat platform, the scaling up of the Prorad portable X-ray portfolio, and the successful launch of Optrascan. The firm also projects a significant margin expansion of approximately 830 basis points, attributed to increased test-kit capacity utilization and improved operational efficiencies.

Innovation Pipeline and Competitive Edge

Jefferies emphasizes that Molbio’s innovation pipeline extends beyond its flagship Truenat product, with multiple new offerings in development. The company has secured 16 patents in India and 191 internationally, underscoring its commitment to innovation in the med-tech space. This focus on research and development positions Molbio as one of the few Indian companies successfully commercializing advanced diagnostic technologies, which could provide a competitive edge in a rapidly evolving market.

Key Highlights

• Molbio’s stock surged 9% following Jefferies’ ‘Buy’ rating.
• Target price set at ₹1,600, indicating a 27% upside potential.
• Projected revenue CAGR of 22% and PAT CAGR of 47% from FY26 to FY29.
• Significant margin expansion expected due to operational efficiencies.
• Innovation pipeline includes multiple new products and extensive patent portfolio.

Investor Note: The positive outlook from Jefferies highlights Molbio’s innovative capabilities and growth potential, making it a compelling investment opportunity for those looking to capitalize on advancements in the med-tech sector.